Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. reported continued operating losses as it advances development of its DurAVR® transcatheter heart valve system and global pivotal Trial. Net sales from legacy tissue products were modest at $1.5 million for the six months ended June 30 2026, up 28% year over year, while the business remains primarily R&D-focused.
R&D expenses rose to $40.8 million and selling, general and administrative costs to $15.3 million, driving an operating loss of $55.0 million and a net loss of $51.7 million for the first half of 2026. Cash used in operating activities was $49.5 million. A major equity raise in January 2026, including a public offering and a strategic $90 million private placement with Medtronic, plus an at-the-market facility of up to $250 million, lifted cash, cash equivalents and restricted cash to $260.9 million at June 30 2026.
Clinically, the company expanded its pivotal Trial with U.S. enrollment following IDE approval, secured U.S. Medicare reimbursement eligibility for trial participants, and obtained French regulatory clearance, supporting broader recruitment. Management states existing liquidity should fund operations for at least 12 months, but material weaknesses in internal control over financial reporting remain under remediation.
L1 Capital Pty Ltd, a more-than-10% owner of Anteris Technologies Global Corp., reported an indirect sale of 174,721 shares of Common Stock on 2026-08-06 at $8.10 per share, described as a sale in the open market or a private transaction. Following this sale, entities controlled and managed by L1 Capital held 5,439,000 shares of Common Stock indirectly. The position includes CHESS Depository Interests representing 5,359,470 underlying common shares and CHESS Depository Interest Warrants over 1,333,334 CHESS Depository Interests with an exercise price of 11.5000 in Australian Dollars (AUD) and an expiration date of 2030-10-30.
L1 Capital Pty Ltd, an Australian investment manager, reports updated beneficial ownership of Anteris Technologies Global Corp. common stock on a passive Schedule 13G amendment. L1 Capital reports beneficial ownership of 13,277,407 shares of common stock and equivalents, representing 13.46% of the class.
The position consists of 6,584,603 shares of common stock, 5,359,470 CHESS Depository Instruments (CDIs), and 1,333,334 CDI warrants, each warrant exercisable within 60 days at AUD 11.50 per CDI. These securities are held across several L1-managed funds, including L1 Long Short and L1 Global Long Short vehicles, all controlled and managed by L1 Capital Pty Ltd.
L1 Capital reports sole voting and dispositive power over all 13,277,407 shares and no shared power. The 13.46% ownership percentage is calculated based on 98,675,537 Anteris common shares outstanding, including shares underlying the CDI warrants held.
FMR LLC filed as a significant holder of ANTERIS TECHNOLOGIES GLOBAL CORP common stock. FMR reports beneficial ownership of 7,325,169 shares, representing 7.5% of the class as of June 30, 2026, with sole dispositive power over all such shares and no shared dispositive power.
FMR reports sole voting power over 7,324,473 shares and no shared voting power. Abigail P. Johnson is separately reported as having sole dispositive power over 7,325,169 shares and no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no other person’s interest exceeds five percent of the outstanding common stock.
L1 Capital Pty Ltd, a ten percent owner of Anteris Technologies Global Corp., reported indirect sales of 14,581 and 480,608 shares of common stock on August 5 and 4, 2026 at prices of $8.23 and in a $8.29–$8.30 range, respectively.
The shares are held through multiple L1-managed funds. After these transactions, entities controlled by L1 Capital indirectly owned 5,359,470 CHESS Depository Interests, each representing one underlying share of common stock exchangeable within 60 days. The trades were not marked as pursuant to a Rule 10b5-1 trading plan.
L1 Capital Pty Ltd, filing as a ten percent owner of Anteris Technologies Global Corp., reported indirect sales of an aggregate 524,404 shares of common stock by funds it manages on July 31 and August 3, 2026, at prices between $8.09 and $8.15 per share.
The report also shows indirect holdings of 5,359,470 CHESS Depository Interests, each representing one underlying share of common stock exchangeable within 60 days.
Anteris Technologies Global Corp. reports that the Federal Court of Australia has granted its application to rectify an inadvertent administrative oversight involving the late lodgement of a cleansing notice under the Corporations Act 2001 (Cth). The matter was heard on 3 August 2026 and the Court granted the relief sought. Anteris has asked the Australian Securities Exchange to lift the trading halt on its securities with effect from market open on 4 August 2026.
On July 31, 2026, Anteris Technologies Global Corp. requested a trading halt in its securities on the Australian Securities Exchange under Listing Rule 17.1 from the commencement of that day’s trading. Trading on The Nasdaq Global Market and The Nasdaq Stock Market is stated to be not impacted.
The company also reports that on July 10, 2026, 44,068 CHESS Depositary Interests (CDIs) were issued following the exercise of certain November 2025 warrants. Due to an administrative oversight, a cleansing notice required under section 708A(6) of the Corporations Act 2001 was not lodged within the prescribed 5 business days. Anteris intends to lodge the cleansing notice now and apply to the Federal Court for relief under section 1322, including an extension of time. The company states that the oversight is not considered price sensitive, that it did not possess excluded information at the time of issue, and that the issued CDIs have been sold.
Funds controlled and managed by L1 Capital Pty Ltd, a 10% owner of Anteris Technologies Global Corp., reported selling a total of 714,138 shares of common stock on July 29 and 30, 2026. Sales included 558,633 shares at $8.20 per share on July 30 and 155,505 shares on July 29 at prices ranging from $8.03–$8.06 per share.
As of July 29, 2026, the funds indirectly held 5,359,470 underlying shares through CHESS Depository Interests, each representing one share of common stock and exchangeable for common shares within 60 days.
L1 Capital Pty Ltd, a 10% holder of Anteris Technologies Global Corp., reported indirect open‑market or private sales of 441,548 shares of common stock on July 27–28, 2026, including 232,817 shares at $8.19 per share and 208,731 shares at $8.09 per share, with individual trades priced between $8.15–$8.25 and $7.90–$8.42, respectively. The transactions and holdings relate to several long‑short funds that L1 Capital controls and manages, which also indirectly held 5,359,470 CHESS Depository Interests, each representing one common share exchangeable within 60 days. L1 Capital states it is exempt from ownership reports under Rule 16a‑2 and does not admit it is obligated to file them.